No Termination Event. There shall not have occurred any event that would permit MLV to terminate this Agreement pursuant to Section 13(a).
Appears in 95 contracts
Sources: At the Market Issuance Sales Agreement, At Market Issuance Sales Agreement (Geron Corp), At Market Issuance Sales Agreement (NephroGenex, Inc.)
No Termination Event. There shall not have occurred any event that would permit MLV to terminate this Agreement pursuant to Section 13(a12(a).
Appears in 25 contracts
Sources: At Market Issuance Sales Agreement (Cardiome Pharma Corp), Sales Agreement (Shale Hunter, LLC), At Market Issuance Sales Agreement (Peregrine Pharmaceuticals Inc)
No Termination Event. There shall not have occurred any event that would permit MLV to terminate this Agreement pursuant to Section 13(a14(a).
Appears in 6 contracts
Sources: At the Market Issuance Sales Agreement (Ligand Pharmaceuticals Inc), At the Market Issuance Sales Agreement (Resource Capital Corp.), At the Market Issuance Sales Agreement (Resource Capital Corp.)
No Termination Event. There shall not have occurred any event that would permit MLV to terminate this Agreement pursuant to Section 13(a).. 25
Appears in 1 contract
Sources: At Market Issuance Sales Agreement (Fieldpoint Petroleum Corp)
No Termination Event. There shall not have occurred any event that would permit MLV to terminate this Agreement pursuant to Section 13(a)) that has not been waived by MLV.
Appears in 1 contract
Sources: At Market Issuance Sales Agreement (Galectin Therapeutics Inc)
No Termination Event. There To the Company’s knowledge, there shall not have occurred any event that would permit MLV to terminate this Agreement pursuant to Section 13(a).
Appears in 1 contract
No Termination Event. There shall not have occurred any event that would permit MLV to terminate this Agreement pursuant to Section 13(a11(a).
Appears in 1 contract
Sources: At the Market Issuance Sales Agreement (CapLease, Inc.)